MoonLake Immunotherapeutics is a Swiss biotech developing SLK, an experimental Nanobody treatment for inflammatory skin and joint diseases. MLTX reports earnings on Wed, Nov 4, 2026. In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 5 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 13 | HC Wainwright & Co. | Target raised | Buy | |
| Jul 20 | HC Wainwright & Co. | Reiterated | Buy | |
| Jul 1 | Leerink Partners | Maintained | Buy | |
| Mar 23 | Wolfe Research | Upgrade | Buy |
Whale Options Flow
90DNo whale options trades in MLTX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLTX is in one of them and how their past MLTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MLTX in an article yet. Here's the latest on the wider market.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company based in Zug, Switzerland, that is developing SLK, an experimental medicine for inflammatory skin and joint diseases. SLK is a Nanobody, a small antibody-like molecule, that blocks two related immune signals called IL-17A and IL-17F. The company is testing SLK in conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis, for patients under the care of skin and joint specialists. It does not yet have an approved product.
- Headquarters
- Zug, Switzerland